Over the past 27 years, the MacLab group, a shareholder of Pharmalink International Limited, has employed the services of leading international research individuals and institutions to identify and isolate the active components within green lipped mussel.

Today the fruits of that long term project are realised in the product we know as Lyprinol. Please look through some of the results below on research that has been completed on our product.

Gibson Brief

The Gibson Brief was a randomised trial conducted on the treatment of arthritis with a lipid extract of Perna canaliculus:

Read more: Gibson Brief

OTC Study

Over the counter (OTC) oral remedies for arthritis and rheumatism: how effective are they?

Read more: OTC Study

Omega - 3 PUFA's

Many studies have reported that certain lipids from fish and other marine sources can have a beneficial effect on our overall health when they should be part of our diet on a routine basis. 

Read more: Omega - 3 PUFA's

Asthma Studies

A clinical trial conducted by Asthma New Zealand and recently published in the Journal of Allergy and Clinical Immunology, points to a trend suggesting that children suffering from asthma may improve their quality of life by taking oil extract derived from Perna canaliculus called PCSO-524® (Lipid fractions of the New Zealand Green lipped mussel) (Tradename Lyprinol®). 

Read more: Asthma Studies

Asthma Studies (2)

The efficacy and safety of an oral standardised lipid extract of New Zealand green lipped mussel (Perna canaliculus) marketed as Lyprinol ® was assessed as maintenance therapy for children with moderate asthma. A total of 71 children aged 6 to 13 years were enrolled in a 16-week, single centre, double-masked, placebo- controlled, parallelgroup trial and randomly assigned to receive either Lyprinol or placebo (2 capsules twice daily). Patients were maintained on as-needed betaagonist therapy and inhaled corticosteroid (ICS) throughout the study.

Read more: Asthma Studies (2)

Asthma research (3)

Marine lipid fraction pcso-524tm (Lyprinol®/Omega xl®) of the new zealand green-lipped mussel attenuates hyperpnea-induced bronchoconstriction in asthma1 : Published in Respiratory Medicine July Edition

Read more: Asthma research (3)

Lipoxygenase Pathway

The anti-inflammatory properties of Lyprinol® have been examined by research scientists at RMIT University, Adelaide University & the University Of Queensland.

 According to this research, Lyprinol® is an effective anti-inflammatory agent (Sir Professor Michael Whitehouse).

Read more: Lipoxygenase Pathway
  • Third Floor, 31 C-D Wyndham St, Central, Hong Kong  
  • +61 755 991 160
  • pharma@plink.com.au

Copyright © 2017 Pharmalink International Limited. All Rights Reserved.
WEB DESIGN